Table1.
Demographics and Clinical Characteristics
| FACIT-F cut off ≤ 34a n (%) |
p-value | ||
|---|---|---|---|
| Demographic characteristics | No n= 130 | Yes n= 39 | |
| Age, Mean (SD), year | 43.2 (13.8) | 48.4 (11.7) | .037* |
| Sex | .450 | ||
| Male | 84 (64.6) | 22 (56.4) | |
| Female | 46 (35.4) | 17 (43.6) | |
| Marital status | .570 | ||
| Married | 82 (63.6) | 27 (69.2) | |
| Not married | 47 (36.4) | 12 (30.8) | |
| Race/Ethnicity | .008* | ||
| Non-Hispanic | 71 (54.6) | 31 (79.5) | |
| Hispanic | 59 (45.4) | 8 (20.5) | |
| Education | .602 | ||
| ≤High school graduate | 35 (27.3) | 11 (28.2) | |
| Associate’s degree/ some college | 32 (25.0) | 11 (28.2) | |
| Bachelor’s degree | 25 (19.5) | 10 (25.6) | |
| Graduate degree | 36 (28.1) | 7 (17.9) | |
| Employment | .006* | ||
| Not working | 96 (75.0) | 20 (51.3) | |
| Working (full-time, part-time, student) | 32 (25.0) | 19 (48.7) | |
| Clinical characteristics | |||
| Time since HCT, Mean (SD), year Range | 5.1 (2.9) | 5.5 (3.0) | .509 |
| HCT-CI Score | .605 | ||
| 0 score | 44 (33.8) | 10 (25.6) | |
| 1 or 2 score | 41 (31.5) | 13 (33.3) | |
| ≥ 3 score | 45 (34.6) | 16 (41.0) | |
| Transplantation risk status | .533 | ||
| Low | 70 (53.8) | 21 (53.8) | |
| Intermediate | 29 (22.3) | 6 (15.4) | |
| High/very high | 31 (23.8) | 12 (30.8) | |
| Conditioning regimen | .799 | ||
| RIC | 57 (43.8) | 18 (46.2) | |
| Myeloablative | 73 (56.2) | 21 (53.8) | |
| Evidence of disease | |||
| Nob | 107 (82.3) | 28 (71.8) | .151 |
| Yes | 23 (17.7) | 11 (28.2) | |
| Immunosuppression intensity | |||
| None | 92 (70.8) | 21 (53.8) | .055 |
| Mild/Moderate/High | 38 (29.2) | 18 (46.2) | |
Numbers may not sum to total due to missing data (n=169).
CR, complete remission; FACT, functional assessment of cancer therapy; HCT, hematopoietic stem cell transplantation; HCT-CI, hematopoietic stem cell transplantation-comorbidity index; MRD, minimal residual disease; PD, progressive disease; PR, partial remission; SD, standard deviation.
a
A total score of 34 or less indicates a clinically meaningful levels of fatigue.
b
Subjects in complete remission and who had not received treatment for their primary disease in the past year.
*
p < .05.